abstract |
The present invention relates to pharmaceutical compositions of metabotropic glutamate 5 (mGlu5) receptor antagonists or a pharmacologically acceptable salt thereof. The compositions contain the therapeutically active compound together with a non-ionic polymer and ionic polymer, binder and fillers either in the form of a matrix pellet, matrix tablet or coated pellets. The compositions provide a pH-independent in vitro release profile with an NMT of 70% in one hour, NMT of 85% in 4 hours and NLT of 80% in 8 hours. The compositions are useful for the treatment of CNS disorders, for example treatment-resistant depression (TRD) and fragile X syndrome. |